Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 66Myelodysplastic Syndromes 38Leukemia, Myelomonocytic, Chronic 26Leukemia 14Myeloproliferative Disorders 10Recurrence 7Lymphoma 7Hematologic Neoplasms 7Neoplasms 6Primary Myelofibrosis 5Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm, Residual 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Glioblastoma 2Carcinoma, Renal Cell 2Anemia, Refractory, with Excess of Blasts 2

Interventions

pembrolizumab 1epacadostat 1copanlisib 1Nivolumab 1Fulvestrant 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Spinocerebellar Degenerations × Azacitidine × Clear all
NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

University of Pittsburgh

Phase 1/2 Withdrawn
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡